| Artificial photosynthesis as a frontier technology for energy sustainability T Faunce, S Styring, MR Wasielewski, GW Brudvig, AW Rutherford, ... Energy & Environmental Science 6 (4), 1074-1076, 2013 | 355 | 2013 |
| Energy and environment policy case for a global project on artificial photosynthesis T Faunce Energy & Environmental Science 6 (3), 695-698, 2013 | 324 | 2013 |
| Uniform format for disclosure of competing interests in ICMJE journals JM Drazen, MB Van Der Weyden, P Sahni, J Rosenberg, A Marusic, ... The Lancet 374 (9699), 1395-1396, 2009 | 249 | 2009 |
| Nanosilver and global public health: international regulatory issues T Faunce, A Watal Nanomedicine 5 (4), 617-632, 2010 | 170 | 2010 |
| Will international human rights subsume medical ethics? Intersections in the UNESCO Universal Bioethics Declaration TA Faunce Journal of medical ethics 31 (3), 173-178, 2005 | 116 | 2005 |
| Decision-analytical modelling in health-care economic evaluations X Sun, T Faunce The European Journal of Health Economics 9, 313-323, 2008 | 108 | 2008 |
| Practical virtue ethics: healthcare whistleblowing and portable digital technology S Bolsin, T Faunce, J Oakley Journal of medical ethics 31 (10), 612-618, 2005 | 107 | 2005 |
| Three Australian whistleblowing sagas: lessons for internal and external regulation TA Faunce, SNC Bolsin Medical Journal of Australia 181 (1), 44-47, 2004 | 101 | 2004 |
| Australian law dictionary L Abbott, J Anderson, DK Anton, K Baker, J Barnes, G Barton, TG Beale, ... Oxford University Press, 2010 | 95 | 2010 |
| Supporting whistleblowers in academic medicine: training and respecting the courage of professional conscience T Faunce, S Bolsin, WP Chan Journal of Medical Ethics 30 (1), 40-43, 2004 | 87 | 2004 |
| Sunscreen safety: the precautionary principle, the Australian therapeutic goods administration and nanoparticles in sunscreens T Faunce, K Murray, H Nasu, D Bowman NanoEthics 2, 231-240, 2008 | 83 | 2008 |
| On-grid batteries for large-scale energy storage: Challenges and opportunities for policy and technology TA Faunce, J Prest, D Su, SJ Hearne, F Iacopi MRS Energy & Sustainability 5, E11, 2018 | 77 | 2018 |
| Integrated research into the nanoparticle–protein corona: a new focus for safe, sustainable and equitable development of nanomedicines TA Faunce, J White, KI Matthaei Nanomedicine 3 (6), 859-866, 2008 | 68 | 2008 |
| 'Linkage'pharmaceutical evergreening in Canada and Australia TA Faunce, J Lexchin Australia and New Zealand Health Policy 4, 1-11, 2007 | 63 | 2007 |
| Developing and teaching the virtue-ethics foundations of healthcare whistle blowing T Faunce Monash Bioethics Review 23 (4), 41-55, 2004 | 47 | 2004 |
| Pharmaceuticals, intellectual property and free trade: the case of the US–Australia Free Trade Agreement P Drahos, B Lokuge, T Faunce, M Goddard, D Henry Prometheus 22 (3), 243-257, 2004 | 47 | 2004 |
| Will the Australia-United States free trade agreement undermine the pharmaceutical benefits scheme? K Harvey, B Lokuge, P Drahos, T Faunce Australasian Medical Association, 2004 | 44 | 2004 |
| Toxicological and public good considerations for the regulation of nanomaterial-containing medical products TA Faunce Expert Opinion on Drug Safety 7 (2), 103-106, 2008 | 43 | 2008 |
| Assessing the impact of the Australia-United States Free Trade Agreement on Australian and global medicines policy T Faunce, E Doran, D Henry, P Drahos, A Searles, B Pekarsky, W Neville Globalization and Health 1, 1-10, 2005 | 43 | 2005 |
| Whistleblowing and scientific misconduct: Renewing legal and virtue ethics foundations TA Faunce, S Jefferys Med. & L. 26, 567, 2007 | 42 | 2007 |
